A glucagonoma is an uncommon neuroendocrine tumor that starts solely in the pancreas and presumably represents 1% of every single neuroendocrine tumor. Harmful glucagonomas are islet cell pancreatic tumors that are found in light of the fact that of glucagonoma syndrome (in which the glucagonoma self-governingly secretes glucagon), on account of neighborhood mass impacts, or incidentally. [1] Glucagonomas start from the alpha-2 cells of the pancreas. Unregulated creation (overproduction) of peptide hormones and development factors, which are not ordinarily communicated in the tissue of starting point, is normal for neuroendocrine tumors. Anomalous creation of these bioactive peptides can prompt huge foundational poisonous outcomes and to the advancement of further tumor growth. [2, 3]
In 75-80% of cases, the glucagonoma begins in harmful structure, and in half of these cases, metastasis exists at finding. The tumor's essence is portrayed by glucagon overproduction, weight reduction, hyperglycemia, diabetes mellitus, hypoaminoacidemia, normochromic and normocytic iron deficiency, and necrolytic transient erythema (NME), which is the most trademark clinical sign (rather than side effect) of this pathology
Posters & Accepted Abstracts: Neurological Disorders
Posters & Accepted Abstracts: Neurological Disorders
Posters & Accepted Abstracts: Neurological Disorders
Posters & Accepted Abstracts: Neurological Disorders
Keynote: Journal of Spine
Keynote: Journal of Spine
Scientific Tracks Abstracts: Neurological Disorders
Scientific Tracks Abstracts: Neurological Disorders
Posters & Accepted Abstracts: Journal of Pediatric Neurology and Medicine
Posters & Accepted Abstracts: Journal of Pediatric Neurology and Medicine
Journal of Clinical Neurology and Neurosurgery received 2 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 